Amyloid β-based therapy for Alzheimer's disease: Challenges, successes and future
Y Zhang, H Chen, R Li, K Sterling… - Signal transduction and …, 2023 - nature.com
Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …
The amyloid-β pathway in Alzheimer's disease
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies
S Paul, E Candelario-Jalil - Experimental neurology, 2021 - Elsevier
Stroke is the leading cause of disability and thesecond leading cause of death worldwide.
With the global population aged 65 and over growing faster than all other age groups, the …
With the global population aged 65 and over growing faster than all other age groups, the …
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease
Alzheimer's disease (AD) is the most common neurodegenerative disorder seen in age-
dependent dementia. There is currently no effective treatment for AD, which may be …
dependent dementia. There is currently no effective treatment for AD, which may be …
[HTML][HTML] Anti-amyloid immunotherapies for Alzheimer's disease: a 2023 clinical update
G Yadollahikhales, JC Rojas - Neurotherapeutics, 2023 - Elsevier
The amyloid cascade hypothesis is a useful framework for therapeutic development in
Alzheimer's disease (AD). Amyloid b 1-42 (Aβ) has been the main target of experimental …
Alzheimer's disease (AD). Amyloid b 1-42 (Aβ) has been the main target of experimental …
History and progress of hypotheses and clinical trials for Alzheimer's disease
PP Liu, Y **e, XY Meng, JS Kang - Signal transduction and targeted …, 2019 - nature.com
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …
Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease
SP Yu, MQ Jiang, SS Shim, S Pourkhodadad… - Molecular …, 2023 - Springer
Stroke and late-onset Alzheimer's disease (AD) are risk factors for each other; the
comorbidity of these brain disorders in aging individuals represents a significant challenge …
comorbidity of these brain disorders in aging individuals represents a significant challenge …
[HTML][HTML] Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain
Brain Derived Neurotrophic Factor (BDNF) is a key molecule involved in plastic changes
related to learning and memory. The expression of BDNF is highly regulated, and can lead …
related to learning and memory. The expression of BDNF is highly regulated, and can lead …
Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer's disease
Alzheimer's disease (AD) is the most common form of dementia but has no effective
treatment. A comprehensive investigation of cell type-specific responses and cellular …
treatment. A comprehensive investigation of cell type-specific responses and cellular …
The amyloid-β oligomer hypothesis: beginning of the third decade
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …